Eli Lilly (LLY) Receivables - Other (2012 - 2026)

Eli Lilly (LLY) has 15 years of Receivables - Other data on file, last reported at $2.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 39.73% year-over-year to $2.7 billion; the trailing twelve-month figure through Mar 2026 stood at $2.7 billion (up 39.73% YoY), and the FY2025 full-year result was $2.4 billion, up 5.51% from the prior year.
• Receivables - Other for Q1 2026 stood at $2.7 billion, up from $2.4 billion in the prior quarter.
• Across five years, Receivables - Other topped out at $3.3 billion in Q3 2025 and bottomed at $1.3 billion in Q2 2022.
• The 5-year median for Receivables - Other is $2.1 billion (2024), against an average of $2.1 billion.
• The widest annual swing landed in 2024, when Receivables - Other slipped 20.02%; it then jumped 90.67% in 2025.
• A 5-year view of Receivables - Other shows it stood at $1.7 billion in 2022, then jumped by 35.05% to $2.2 billion in 2023, then grew by 1.08% to $2.3 billion in 2024, then advanced by 5.51% to $2.4 billion in 2025, then increased by 14.74% to $2.7 billion in 2026.
• The last three Receivables - Other figures came in at $2.7 billion (Q1 2026), $2.4 billion (Q4 2025), and $3.3 billion (Q3 2025), per Business Quant data.

Peer Comparison